Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Oncology-based In-vivo CRO Market Outlook (2023 to 2033)

The global Oncology-based In-vivo CRO Market was valued at around US$ 1 Billion in 2021. With a projected CAGR of 10.9% for the next ten years, the market is likely to reach a valuation of nearly US$ 2.9 by the end of 2033. The absolute dollar opportunity in the Oncology-based In-vivo CRO Market is anticipated to be at US$ 1.8 Billion by 2033.

Attributes Details
Oncology-based In-vivo CRO Market Size (2021) US$ 1 Billion
Oncology-based In-vivo CRO Market Size (2023) US$ 1.1 Billion
Projected Market Value (2033) US$ 2.9 Billion
Global Market Growth Rate (2023 to 2033) 10.9% CAGR
Share of Top 5 Countries 56%
Key Companies Profiled
  • The Jackson Laboratory
  • EVOTEC
  • WuXi AppTec
  • Toxicon Inc.
  • Crown Bioscience
  • Taconic Biosciences
  • Eurofins Scientific
  • ICON Plc
  • Charles River Laboratory
  • Covance
  • Others

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Oncology-based In-vivo CRO Market from 2018 to 2021 Vs Market Outlook for 2023 to 2033

Future Market Insights reveals that the Oncology-based in-vivo CRO market increased at a CAGR of 8.9% from 2018 to 2022 and is expected to achieve a growth rate of 10.9% from 2023 to 2033.

Oncology-based in-vivo CRO is expected to grow in the forecasted years due to a rise in the incidence of Oncology-based cases and the need to develop new drugs for the treatment of cancer patients. According to the World Health Organization, the global cancer burden increased to 19.3 million new cases and caused an anticipated 10 million deaths in 2020. This is driving the companies to outsource basic research activities and increase efficiency by focusing on key areas of development.

Why companies are shifting to outsourcing Oncology-based research and development activities to CROs?

An increasing number of drugs being developed, new therapeutic modalities, advanced clinical practices, and emerging technologies have been driving the demand for Oncology-based in-vivo CRO. With the rising number of pharmaceutical companies, research and development activities are being outsourced to CRO services due to lower costs and focus on aspects that are more vital. CROs have gained the momentum to offer pharmaceutical organizations their research and development services and eliminate the hurdles that the companies face.

Companies generally outsource activities ranging from basic research to efficacy tests in animal models as well as late-stage clinical trials. Moreover, oncology is one of the most studied and researched domains due to the prevalence of cancer patients worldwide. With a number of oncology drugs being approved in recent years, necessitating new treatment options for patients, oncology still remains a challenging area for research and development. This is expected to propel the growth of Oncology-based in-vivo CRO.

Based on the research conducted by the Tufts Center for the study of Drug Development (CSDD), more than 75% of the top management of pharmaceutical companies agree that CROs are more time-efficient than internal teams, thereby expanding the scope of outsourcing. Besides, owing to specialization in the respective domain due to years of experience in the business, CROs are able to perform the task at an exceptionally greater speed.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What factors are hampering the growth of the Oncology-based In-vivo CRO Market?

Drug development for cancer is a research-intensive study. The development of the oncology-based in-vivo CRO industry is being constrained by a lack of infrastructure and financial support for research operations, particularly in low- and middle-income countries. Organizations engaged in oncology practices do not have enough resources to conduct research studies for the patients and are dependent upon the trials conducted by high-income countries, to provide focused and quality patient care. Moreover, strict regulatory approvals are another key obstacle fuelling the growth of Oncology-based in-vivo CRO.

Region-wise Insights

How Oncology-based In-vivo CRO Market is Shaping in North America?

The market in North America is likely to witness growth due to increasing research and development activities and demand to lower total trial expenditure. The availability of sizable investments in this area is expected to have an impact on the research efforts in the forecast period. Key pharmaceutical and life science firms that play a key role in the development of new drugs are also present in the region. The global oncology-based in-vivo CRO market in the region is anticipated to boost market expansion due to well-planned funding and advantageous regulatory policies.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

USA Oncology-based In-vivo CRO Market Analysis

Oncology-based In-vivo CRO Market in the USA. is valued at US$ 1.2 Billion by 2033. Revenue through Oncology-based in-vivo CRO in the USA grew at 8.5% from 2018 to 2022 and is projected to achieve a growth rate of 11% over the forecast period.

This can be attributed due to the presence of several CROs present in the USA They are continuously getting funds and grants from government organizations to progress in the development of Oncology-based drug development. For instance, The Maine Cancer Genomics Initiative by Jackson laboratory is generating awareness and providing access to advanced genomic treatments, by characterizing the genetic profile of each patient’s cancer, thereby expanding the scope of educational programs in cancer genomics. The absolute dollar opportunity growth in Oncology-based in-vivo CROs in the USA is US$ 827.5 Billion between 2023 and 2033.

China Oncology-based In-vivo CRO Market Analysis

Asia-Pacific has seen an emergence of Oncology-based research facilities due to increased research and developments in the region. For instance, in October 2020, Crown Bioscience expanded its Asia Pacific capacity by opening a new oncology-focused research facility in Zhongshan, China. The new research facility will offer 2,000 m2 to manage the in-vivo oncology platform.

Its currently existing facility is located in Beijing, Taicang and Suzhou, and Taiwan. Oncology-based in-vivo CRO facility in China is valued at US$ 145.1 Million by 2033. The market accounted for a CAGR of 12.7% in China from 2018 to 2022. With the ongoing development of Oncology-based in-vivo CRO in China, it is no doubt that the absolute dollar opportunity growth will reach US$ 95.8 Million by 2033.

UK Oncology-based In-vivo CRO Market Analysis

The market in the UK is projected to reach a valuation of US$ 194 Million by 2033. Growing at a CAGR of 11.8% from 2023 to 2033, the market is expected to gross an absolute dollar opportunity of 130 Million.

Category-wise Insights

How Oncology-based in-vivo CRO Market is being Driven by Solid Tumors?

Solid tumors accounted for the top segment in oncology based in-vivo CRO. Revenue through solid tumors in the market grew at a CAGR of 8.6% during the period of 2018 to 2022. The projected CAGR of solid tumors in the Oncology-based In-vivo CRO Market is expected to be 11.2% over the forecast period. Around 90% of adult human cancers are represented by solid tumors.

The existence of over 800 novel compounds in the pipelines of key pharmaceutical firms, the accessibility of grants from organizations like the NIH and NCI, and the current therapeutic treatment gap for solid tumors are the elements driving increased research in the field of solid tumors.

Competitive Landscape

Companies involved in the Oncology-based In-vivo CRO Market are largely aiming at setting up clinical facilities, winning orders, and aiming at developing drugs for the treatment of cancer. The key companies operating in the Oncology-based In-vivo CRO Market include The Jackson Laboratory, EVOTEC, WuXi AppTec, Toxicon Inc., Crown Bioscience, Taconic Biosciences, Eurofins Scientific, ICON Plc, Charles River Laboratory, and Covance.

Some of the recent developments by key providers of Oncology-based in-vivo CRO are as follows:

  • In July 2022, researchers from Jackson Laboratory (JAX) were successful in demonstrating, why patients with BRCA mutations are able to respond properly and develop resistance from platinum-based therapy than BRCA1 promoter methylation. The team used patient data, patient-derived xenograft (PDX) mouse models, and engineered cancer cell lines. They also developed an algorithm for TNBC and ovarian cancer that shows the potential response to chemotherapy and prevents patients from overtreatment.
  • In May 2022, The Jackson Laboratory team deployed machine learning to capture precise insights about cancer patients and interpret tumor images faster and more accurately providing the possibility of more focused treatment without the need for additional testing.
  • In October 2021, Charles River Laboratories in Japan was acquired by Jackson Laboratory, which is now known as Jackson Laboratory Japan. JAX provides access to animal models, resources, and scientific support to the new company and will assist researchers to make scientific advancements and breakthroughs in drug development.
  • In October 2021, Crown Bioscience launched the 3D ex Vivo Patient Tissue Platform. The platform uses the tumor tissue of the patient, which is extracted by biopsies, surgical resections, and ascites or from the samples of pleural effusion and is processed to preserve the tumor microenvironment.
  • In April 2021, Evotec SE invested in OxVax, an immune-oncology company built on Oxford University research that enables the creation of the next generation of cancer vaccines with the potential to outperform existing methods. OxVax’s vaccine will train the body system to target tumors and eliminate them.
  • In April 2021, Evotec partnered with Kazia Therapeutics for the development and commercialization of Evotec’s oncology project EVT801. Evotec aims to conduct the phase I trial of EVT801 under the sponsorship of Kazia.
  • In November 2020, Evotech SE partnered with Rappta Therapeutics to develop a small molecule that reactivates PP2A, which suppresses the response for multiple oncogenic signaling pathways responsible for cancer progression.

Similarly, recent developments related to companies involved in the Oncology-based in-vivo CRO market have been tracked by the team at Future Market Insights, which is available in the full report.

Key Segments Covered in Oncology-based in-vivo CRO Industry Survey

By Indication:

  • Blood Cancer
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Solid Tumors
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft
  • Other Indications
    • Syngeneic Model
    • Patient Derived Xenograft (PDX)
    • Xenograft

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the Oncology-based In-vivo CRO market value in 2023?

The market is valued at US$ 1 Billion in 2023.

What is the CAGR from 2023 to 2033?

The market’s CAGR from 2023 to 2033 will be 10.9%.

How is the historical performance of the market?

From 2018 to 2022, the market registered an 8.9% CAGR.

What is China’s expected revenue in 2033?

China will generate US$ 145.1 million revenue by 2033.

Which is the key segment by indication?

Solid tumors will be the key segment.

Table of Content

1. Executive Summary | Oncology-Based In-vivo CRO Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        5.3.1. Blood Cancer

            5.3.1.1. Syngeneic Model

            5.3.1.2. Patient-Derived Xenograft (PDX)

            5.3.1.3. Xenograft

        5.3.2. Solid Tumours

            5.3.2.1. Syngeneic Model

            5.3.2.2. Patient-Derived Xenograft (PDX)

            5.3.2.3. Xenograft

        5.3.3. Other Indications

            5.3.3.1. Syngeneic Model

            5.3.3.2. Patient-Derived Xenograft (PDX)

            5.3.3.3. Xenograft

    5.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    6.1. Introduction

    6.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    6.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        6.3.1. North America

        6.3.2. Latin America

        6.3.3. Europe

        6.3.4. Asia Pacific

        6.3.5. Middle East & Africa (MEA)

    6.4. Market Attractiveness Analysis By Region

7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    7.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    7.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        7.2.1. By Country

            7.2.1.1. USA

            7.2.1.2. Canada

        7.2.2. By Indication

    7.3. Market Attractiveness Analysis

        7.3.1. By Country

        7.3.2. By Indication

    7.4. Key Takeaways

8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. Brazil

            8.2.1.2. Mexico

            8.2.1.3. Rest of Latin America

        8.2.2. By Indication

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Indication

    8.4. Key Takeaways

9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Germany

            9.2.1.2. UK

            9.2.1.3. France

            9.2.1.4. Spain

            9.2.1.5. Italy

            9.2.1.6. Russia

            9.2.1.7. Rest of Europe

        9.2.2. By Indication

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Indication

    9.4. Key Takeaways

10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. China

            10.2.1.2. Japan

            10.2.1.3. India

            10.2.1.4. South Korea

            10.2.1.5. Australia

            10.2.1.6. Rest of APAC

        10.2.2. By Indication

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Indication

    10.4. Key Takeaways

11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. South Africa

            11.2.1.2. Saudi Arabia

            11.2.1.3. UAE

            11.2.1.4. Israel

            11.2.1.5. Rest of MEA

        11.2.2. By Indication

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Indication

    11.4. Key Takeaways

12. Key Countries Market Analysis

    12.1. USA

        12.1.1. Pricing Analysis

        12.1.2. Market Share Analysis, 2022

            12.1.2.1. By Indication

    12.2. Canada

        12.2.1. Pricing Analysis

        12.2.2. Market Share Analysis, 2022

            12.2.2.1. By Indication

    12.3. Brazil

        12.3.1. Pricing Analysis

        12.3.2. Market Share Analysis, 2022

            12.3.2.1. By Indication

    12.4. Mexico

        12.4.1. Pricing Analysis

        12.4.2. Market Share Analysis, 2022

            12.4.2.1. By Indication

    12.5. Germany

        12.5.1. Pricing Analysis

        12.5.2. Market Share Analysis, 2022

            12.5.2.1. By Indication

    12.6. UK

        12.6.1. Pricing Analysis

        12.6.2. Market Share Analysis, 2022

            12.6.2.1. By Indication

    12.7. France

        12.7.1. Pricing Analysis

        12.7.2. Market Share Analysis, 2022

            12.7.2.1. By Indication

    12.8. Spain

        12.8.1. Pricing Analysis

        12.8.2. Market Share Analysis, 2022

            12.8.2.1. By Indication

    12.9. Italy

        12.9.1. Pricing Analysis

        12.9.2. Market Share Analysis, 2022

            12.9.2.1. By Indication

    12.10. Russia

        12.10.1. Pricing Analysis

        12.10.2. Market Share Analysis, 2022

            12.10.2.1. By Indication

    12.11. China

        12.11.1. Pricing Analysis

        12.11.2. Market Share Analysis, 2022

            12.11.2.1. By Indication

    12.12. Japan

        12.12.1. Pricing Analysis

        12.12.2. Market Share Analysis, 2022

            12.12.2.1. By Indication

    12.13. India

        12.13.1. Pricing Analysis

        12.13.2. Market Share Analysis, 2022

            12.13.2.1. By Indication

    12.14. South Korea

        12.14.1. Pricing Analysis

        12.14.2. Market Share Analysis, 2022

            12.14.2.1. By Indication

    12.15. Australia

        12.15.1. Pricing Analysis

        12.15.2. Market Share Analysis, 2022

            12.15.2.1. By Indication

    12.16. South Africa

        12.16.1. Pricing Analysis

        12.16.2. Market Share Analysis, 2022

            12.16.2.1. By Indication

    12.17. Saudi Arabia

        12.17.1. Pricing Analysis

        12.17.2. Market Share Analysis, 2022

            12.17.2.1. By Indication

    12.18. UAE

        12.18.1. Pricing Analysis

        12.18.2. Market Share Analysis, 2022

            12.18.2.1. By Indication

    12.19. Israel

        12.19.1. Pricing Analysis

        12.19.2. Market Share Analysis, 2022

            12.19.2.1. By Indication

13. Market Structure Analysis

    13.1. Competition Dashboard

    13.2. Competition Benchmarking

    13.3. Market Share Analysis of Top Players

        13.3.1. By Regional

        13.3.2. By Indication

14. Competition Analysis

    14.1. Competition Deep Dive

        14.1.1. Charles River Laboratory

            14.1.1.1. Overview

            14.1.1.2. Product Portfolio

            14.1.1.3. Profitability by Market Segments

            14.1.1.4. Sales Footprint

            14.1.1.5. Strategy Overview

                14.1.1.5.1. Marketing Strategy

        14.1.2. ICON Plc

            14.1.2.1. Overview

            14.1.2.2. Product Portfolio

            14.1.2.3. Profitability by Market Segments

            14.1.2.4. Sales Footprint

            14.1.2.5. Strategy Overview

                14.1.2.5.1. Marketing Strategy

        14.1.3. Covance

            14.1.3.1. Overview

            14.1.3.2. Product Portfolio

            14.1.3.3. Profitability by Market Segments

            14.1.3.4. Sales Footprint

            14.1.3.5. Strategy Overview

                14.1.3.5.1. Marketing Strategy

        14.1.4. Eurofins Scientific

            14.1.4.1. Overview

            14.1.4.2. Product Portfolio

            14.1.4.3. Profitability by Market Segments

            14.1.4.4. Sales Footprint

            14.1.4.5. Strategy Overview

                14.1.4.5.1. Marketing Strategy

        14.1.5. Taconic Biosciences

            14.1.5.1. Overview

            14.1.5.2. Product Portfolio

            14.1.5.3. Profitability by Market Segments

            14.1.5.4. Sales Footprint

            14.1.5.5. Strategy Overview

                14.1.5.5.1. Marketing Strategy

        14.1.6. Crown Bioscience

            14.1.6.1. Overview

            14.1.6.2. Product Portfolio

            14.1.6.3. Profitability by Market Segments

            14.1.6.4. Sales Footprint

            14.1.6.5. Strategy Overview

                14.1.6.5.1. Marketing Strategy

        14.1.7. Toxikon, Inc.

            14.1.7.1. Overview

            14.1.7.2. Product Portfolio

            14.1.7.3. Profitability by Market Segments

            14.1.7.4. Sales Footprint

            14.1.7.5. Strategy Overview

                14.1.7.5.1. Marketing Strategy

        14.1.8. WuXi AppTec

            14.1.8.1. Overview

            14.1.8.2. Product Portfolio

            14.1.8.3. Profitability by Market Segments

            14.1.8.4. Sales Footprint

            14.1.8.5. Strategy Overview

                14.1.8.5.1. Marketing Strategy

        14.1.9. EVOTEC

            14.1.9.1. Overview

            14.1.9.2. Product Portfolio

            14.1.9.3. Profitability by Market Segments

            14.1.9.4. Sales Footprint

            14.1.9.5. Strategy Overview

                14.1.9.5.1. Marketing Strategy

        14.1.10. The Jackson Laboratory

            14.1.10.1. Overview

            14.1.10.2. Product Portfolio

            14.1.10.3. Profitability by Market Segments

            14.1.10.4. Sales Footprint

            14.1.10.5. Strategy Overview

                14.1.10.5.1. Marketing Strategy

15. Assumptions & Acronyms Used

16. Research Methodology

Explore Healthcare Insights

View Reports

Oncology-Based In-vivo CRO Market